Enstilar Aerosol, Foam
NDC Package 50222-302-60
Package Information
Enstilar (calcipotriene and betamethasone dipropionate) aerosols is enstilar® (calcipotriene and betamethasone dipropionate) Foam is indicated for the topical treatment of plaque psoriasis in patients 12 years and older. This formulation utilizes a aerosol, foam delivery system. Marketed by Leo Pharma Inc., this product is identified by NDC 50222-302 and is authorized under FDA application NDA207589.
Identification & Billing
- RxCUI: 1716094 - calcipotriene 0.005 % / betamethasone propionate 0.064 % Topical Foam
- RxCUI: 1716094 - betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Foam
- RxCUI: 1716099 - Enstilar 0.005 % / 0.064 % Topical Foam
- RxCUI: 1716099 - betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Foam [Enstilar]
- RxCUI: 1716099 - Enstilar (calcipotriene 0.005 % / betamethasone dipropionate 0.064 % ) Topical Foam
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50222 - Leo Pharma Inc.
- 50222-302 - Enstilar
- 50222-302-60 - 1 CAN in 1 CARTON / 60 g in 1 CAN
- 50222-302 - Enstilar
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (50222-302). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50222-302-60 identifies a specific commercial package of 1 can in 1 carton / 60 g in 1 can of Enstilar, a human prescription drug labeled by Leo Pharma Inc.. This aerosol, foam is formulated for topical use and contains calcipotriene monohydrate; betamethasone dipropionate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Leo Pharma Inc. on October 16, 2015. The current certification is valid through December 31, 2026.
How is this Leo Pharma Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50222030260. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.